Key Highlights
- Berenberg elevated GSK’s rating from “hold” to “buy,” increasing price target from £20 to £22
- Shares advanced 0.4% to reach £18.62 during early London market hours
- The pharmaceutical company trades at a 23% valuation discount compared to European sector counterparts
- Company announced acquisition of trispecific T cell-engager technology from Chimagen Biosciences valued at $750 million
- The acquired Chimagen asset focuses on multiple myeloma treatment with Phase 1 trials anticipated in 2027
Shares of GSK advanced 0.4% to £18.62 during Tuesday’s early London session following Berenberg’s decision to elevate the pharmaceutical manufacturer from “hold” to “buy” status while simultaneously increasing the price objective from £20 to £22.
The rating enhancement arrives as Berenberg highlighted an increasingly robust late-stage development portfolio and accelerated deal activity as justification for closing the current valuation disparity.
The company’s shares command a multiple of 9.6 times projected 2027 adjusted earnings. This represents a 23% markdown versus European pharmaceutical industry peers trading at 12.4 times. Berenberg contends this valuation differential has grown excessively large.
The brokerage firm observed that external sourcing accounted for 10 of GSK’s 11 innovative Phase 3 programs. Six late-stage candidates possess potential to deliver peak yearly revenues exceeding £2 billion each.
Berenberg projects GSK will achieve approximately £39 billion in sales by 2031. This figure exceeds market consensus estimates hovering near £36 billion while approaching the company’s internal target of over £40 billion.
Upcoming Pipeline Milestones
Recently introduced medications Exdensur and Blenrep are anticipated to drive expansion. Berenberg identifies additional growth opportunities from bepirovirsen, Nuvalent’s lung cancer programs, and the oncology antibody-drug conjugate collaboration with Hansoh.
The firm highlighted two imminent regulatory determinations. U.S. regulators are scheduled to decide on bepirovirsen for hepatitis B treatment by October 26, while a verdict on neladalkib for second-line ALK-positive lung cancer is anticipated by November 27.
Phase 3 results and proof-of-concept information are projected within the coming 12 months spanning small-cell lung cancer, HIV, asthma, food allergy, and bronchiectasis initiatives.
The company’s efficiency initiative aims to deliver £1.9 billion in yearly savings by 2029. Berenberg indicated this should safeguard research investment and maintain margin stability despite anticipated erosion of high-margin oral HIV medications starting in 2028.
Patent expiration challenges for dolutegravir represent a recognized obstacle. Berenberg’s above-market projections demonstrate conviction that pipeline candidates and operational efficiency will offset this pressure.
Chimagen Partnership Strengthens Multiple Myeloma Portfolio
In a separate announcement, GSK revealed an agreement to obtain a trispecific T cell-engager platform from Chimagen Biosciences. The transaction encompasses complete worldwide rights with aggregate potential consideration reaching $750 million through development and commercialization milestone payments.
The T cell-engager technology works by simultaneously engaging T cells while addressing two distinct tumor-associated antigens. The asset is projected to commence Phase 1 clinical studies in 2027.
Multiple myeloma ranks as the third most prevalent blood malignancy worldwide, affecting approximately 180,000 newly diagnosed individuals annually. While manageable, the condition remains incurable with existing therapies.
Hesham Abdullah, who leads GSK’s Global Oncology R&D division, stated the transaction “strengthens GSK’s ambitions in blood cancer” while introducing an additional therapeutic possibility for patients.
The Chimagen transaction expands upon an established partnership between both organizations. GSK had previously committed to acquiring CMG1A46, a dual CD19 and CD20-targeted T cell-engager presently undergoing Phase 1 evaluation for B-cell malignancies.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
